MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ejhf.1920

Медицинская библиотека · European journal of heart failure · 2020

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.

Lyon Alexander R, Dent Susan, Stanway Susannah, Earl Helena, Brezden-Masley Christine, Cohen-Solal Alain, Tocchetti Carlo G, Moslehi Javid J, Groarke John D, Bergler-Klein Jutta, Khoo Vincent, Tan Li Ling, Anker Markus S, von Haehling Stephan, Maack Christoph, Pudil Radek, Barac Ana, Thavendiranathan Paaladinesh, Ky Bonnie, Neilan Tomas G, Belenkov Yury, Rosen Stuart D, Iakobishvili Zaza, Sverdlov Aaron L, Hajjar Ludhmila A, Macedo Ariane V S, Manisty Charlotte, Ciardiello Fortunato, Farmakis Dimitrios, de Boer Rudolf A, Skouri Hadi, Suter Thomas M, Cardinale Daniela, Witteles Ronald M, Fradley Michael G, Herrmann Joerg, Cornell Robert F, Wechelaker Ashutosh, Mauro Michael J, Milojkovic Dragana, de Lavallade Hugues, Ruschitzka Frank, Coats Andrew J S, Seferovic Petar M, Chioncel Ovidiu, Thum Thomas, Bauersachs Johann, Andres M Sol, Wright David J, López-Fernández Teresa, Plummer Chris, Lenihan Daniel

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАConsensus StatementПеревод в очереди

Аннотация

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.

Для цитирования: Lyon Alexander R, Dent Susan, Stanway Susannah, Earl Helena, Brezden-Masley Christine, Cohen-Solal Alain, Tocchetti Carlo G, Moslehi Javid J, Groarke John D, Bergler-Klein Jutta, Khoo Vincent, Tan Li Ling, Anker Markus S, von Haehling Stephan, Maack Christoph, Pudil Radek, Barac Ana, Thavendiranathan Paaladinesh, Ky Bonnie, Neilan Tomas G, Belenkov Yury, Rosen Stuart D, Iakobishvili Zaza, Sverdlov Aaron L, Hajjar Ludhmila A, Macedo Ariane V S, Manisty Charlotte, Ciardiello Fortunato, Farmakis Dimitrios, de Boer Rudolf A, Skouri Hadi, Suter Thomas M, Cardinale Daniela, Witteles Ronald M, Fradley Michael G, Herrmann Joerg, Cornell Robert F, Wechelaker Ashutosh, Mauro Michael J, Milojkovic Dragana, de Lavallade Hugues, Ruschitzka Frank, Coats Andrew J S, Seferovic Petar M, Chioncel Ovidiu, Thum Thomas, Bauersachs Johann, Andres M Sol, Wright David J, López-Fernández Teresa, Plummer Chris, Lenihan Daniel. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.. European journal of heart failure. 2020. DOI: 10.1002/ejhf.1920.

Предметные рубрики MeSH

AgedAndrogen AntagonistsAntineoplastic AgentsCardiovascular DiseasesFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedNeoplasmsRisk AssessmentRisk Factors
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.